Korro Bio, Inc. announced it has dosed the first cohort of participants in its Phase 1/2 clinical trial, named ANCHOR, for its drug candidate KRRO-121. The trial is evaluating the RNA-editing oligonucleotide for the potential treatment of hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy.
Key Details
- Trial & Drug: The ANCHOR Phase 1/2 study is assessing KRRO-121, an RNA-editing therapy, in healthy volunteers and patients with Urea Cycle Disorders.
- Timeline: Dosing in UCD patients is expected to begin in the first half of 2027, with an interim clinical readout anticipated in the second half of 2027.
- Current Status: The first cohort of healthy volunteers has been administered a single dose of 2mg/kg in the initial single ascending dose (SAD) part of the trial.